Abstract 221P
Background
First-line immune checkpoint inhibitor (ICI) for cisplatin-ineligible metastatic urothelial carcinoma patients has been approved by FDA and EMA. However, there is still a lack of evidence to directly compare treatment efficacy between ICI and conventional carboplatin-based chemotherapy. Here we conduct a retrospective analysis to compare the survival outcome between ICI and carboplatin treatment.
Methods
The study enrolled 130 metastatic urothelial carcinoma patients who underwent first-line ICI or carboplatin-based chemotherapy at Kaohsiung and Linko Chang Gung Memorial Hospital between May 2001 and Jun 2019. Kaplan-Meier analyses and Cox proportional regression models were used for univariate and multivariate survival analyses.
Results
In total, there were 44 patients (34%) in the ICI group and 86 patients (66%) in the carboplatin group. The median OS was insignificantly different between ICI and carboplatin groups, accounting for 11.1 and 9.5 months (p = 0.46), respectively. The median PFS in ICI and carboplatin groups were 2.5 and 3.7 months, respectively (p = 0.92). On subgroup analysis, OS was significantly worse for ICI treatment in patients with elevated pretreatment white blood cell count (WBC ≥ 10000 × 103/μL) compared with those on carboplatin group (HR 2.41, 95% CI 1.1 – 5.25, p = 0.03).
Conclusions
In this real-world data analysis, we didn’t show significant survival difference in first-line treatment with ICI and carboplatin-based chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
97P - The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer
Presenter: Jong Hoon Lee
Session: Poster display session
Resources:
Abstract
98P - Influence of DPYD*9, DPYD*6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer patients
Presenter: Ashok Varma
Session: Poster display session
Resources:
Abstract
99P - Patient-derived tumour model by new culture method leading to the precision medicine
Presenter: Norikatsu Miyoshi
Session: Poster display session
Resources:
Abstract
100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer
Presenter: Kai-Yuan Lin
Session: Poster display session
Resources:
Abstract
101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
Presenter: Chang Wang
Session: Poster display session
Resources:
Abstract
102P - Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study
Presenter: Kazuhiro Watanabe
Session: Poster display session
Resources:
Abstract
103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy
Presenter: Yanfei Yang
Session: Poster display session
Resources:
Abstract
104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer
Presenter: Sare Hosseini
Session: Poster display session
Resources:
Abstract
105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer
Presenter: Shuohui Dong
Session: Poster display session
Resources:
Abstract
106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum
Presenter: Yakov Ten
Session: Poster display session
Resources:
Abstract